Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, announced today the successful completion of an impressive $73 million financing round. The investment was led by Hatteras Investment Partners and saw new investors ARCH Venture Partners and Moore Strategic Ventures join the round, alongside existing investors Newpath Partners, 8VC and Alexandria Venture Investments.
Myeloid is making great strides in merging immunology and RNA science to create a robust portfolio of clinical-stage products that address the pressing needs of cancer patients. We are delighted to welcome top-notch investors to the team, who share our vision of transforming healthcare and accelerating progress towards our goals.
Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, said, “We are excited to be making such remarkable progress in our mission to improve the lives of those affected by cancer.”
Myeloid is thrilled to announce the completion of a financing round that will help propel the development of its groundbreaking cell therapy program, MT-101, in Phase 1/2 trials for T cell lymphoma.
Furthermore, the funds will also be used to accelerate the development of MT-302, a first-of-its-kind TROP2-FcA mRNA-LNP product, into Phase 1/2 trials for TROP2-expressing tumors. With these resources, Myeloid can now take its promising in vivo programming candidates to the clinic and revolutionize the way we treat cancer.
Hatteras, proud to support Myeloid through its next phase of growth, is highly encouraged by the innovation, execution, and clinical development progress demonstrated by the company. This field-leading company is disrupting the status quo and accelerating the pace of innovation, and Hatteras’s General Partner Clay B. Thorp is optimistic that these approaches will result in a meaningful clinical outcome for patients.
About MT-302
Myeloid has engineered an innovative in vivo platform that unlocks the potential of myeloid cells to stimulate broader anti-tumor adaptive immunity. By utilizing its proprietary ATAK™ CAR receptor library, Myeloid has enabled delivery of mRNA encapsulated in lipid-nanoparticles (LNPs) to myeloid cells, resulting in potent tumor killing in multiple cold tumor models.
Myeloid’s lead in vivo program, MT-302, is a revolutionary CAR designed for expression within the myeloid compartment and targeting TROP2 – a tumor associated antigen expressed on some of the most difficult to treat cancers. Treatment with MT-302 has already demonstrated monotherapy activity in a TROP2/TNBC model, emphasizing the power of programmed myeloid cells.
As opposed to TROP2-ADC approaches, MT-302 has the potential to engage the full immune response. Myeloid is on track to initiate a Phase 1/2 clinical study with MT-302 for patients with TROP2-expressing tumors in 2023, offering hope for those with challenging cancer types.
About MT-101
Myeloid’s ground-breaking MT-101 is the first autologous CAR monocyte to be developed using the company’s proprietary ATAK™ platform. By harnessing the power of myeloid cells to penetrate tumors and promote anti-tumor activity, MT-101 targets CD5, a surface receptor present in more than 75% of peripheral T cell lymphomas.
These engineered cells are created ex vivo with the mRNA-strand coding for the CAR, and delivered back to the patient within 8 days. Thanks to Myeloid’s patented processes, the ATAK™ CAR is now available to patients worldwide.
The IMAGINE clinical trial (NCT05138458) is an exciting opportunity to evaluate the potential of a novel therapy, MT-101, in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). This Phase 1/2, multicenter, open-label, first-in-human, multiple ascending dose study is enrolling participants for the dose-escalation portion, with or without conditioning therapy. Be part of this groundbreaking trial and help shape the future of cancer treatment!
RetroT™
Myeloid’s groundbreaking RetroT™ technology is revolutionizing genetic engineering, allowing for the delivery of gene-sized pieces of DNA into the genome in a virus-free manner. This cutting-edge technology is larger than any existing gene editing technology, and has the potential to reverse a range of genetic errors in situ.
In March 2022, Myeloid entered into a research collaboration agreement with Prime Medicine, Inc. to develop and accelerate RetroT™, offering a new level of therapeutic potential for genetic editing.
About Myeloid Therapeutics
Myeloid Therapeutics is revolutionizing cancer treatment by harnessing the power of mRNA-immunotherapy. Our proprietary platform combines the latest breakthroughs in RNA, immunology, and medicine to create personalized treatments tailored to the individual needs of each patient.
We are pushing the boundaries of cancer treatment by exploring innovative modalities such as autologous cell therapies, in vivo cell programming using mRNA, and RNA-based gene-editing using RetroT™.